Vancomycin

Vancocin / Firvanq

Vancomycin is a glycopeptide antibiotic originally isolated in the 1950s from a soil bacterium (Amycolatopsis orientalis). Its molecule is a complex, sugar-decorated peptide scaffold rather than a simple linear chain, and that structure is central to how it works. Vancomycin binds tightly to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of the building blocks bacteria use to construct their cell wall (peptidoglycan). By capping those precursors, it physically blocks the cross-linking enzymes from finishing the wall, so the bacterium cannot build a stable envelope and dies. Because this target sits on the outside of the cell wall, vancomycin does not need to enter the cell — but the same bulk means it cannot cross the outer membrane of Gram-negative bacteria, which is why its activity is limited to Gram-positive organisms. Clinically, vancomycin is one of the most important antibiotics in hospital medicine. It is a mainstay for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other resistant Gram-positive bacteria, and is used for bacteremia, endocarditis, bone and joint infections, skin and soft-tissue infections, and empiric coverage in seriously ill patients until cultures return. Intravenous vancomycin is standard for these systemic infections. A separate, distinct use exploits the fact that oral vancomycin is barely absorbed from the gut: taken by mouth it stays in the intestine and is a first-line treatment for Clostridioides difficile (C. diff) colitis, acting locally where that infection lives. Vancomycin requires careful stewardship. Dosing is weight- and kidney-function-based and is guided by drug-level monitoring (increasingly AUC-based rather than simple troughs) to balance efficacy against kidney toxicity. Rapid infusion can trigger 'vancomycin flushing reaction' (historically 'red man syndrome'), an infusion-rate-related histamine release that is prevented by slowing the infusion. The emergence of vancomycin-resistant enterococci (VRE) and reduced-susceptibility staphylococci is a serious concern that drives appropriate-use programs. Vancomycin is an approved prescription medicine and a WHO Essential Medicine — it is not a wellness or research peptide, and it is always used under medical supervision.